#### Wisconsin State Laboratory of Hygiene Board of Directors Meeting September 21, 2021 Madison, Wisconsin

#### DATE: September 15, 2021

TO: Dean Robert N. Golden, MD, UW-SMPH – Dr. Richard Moss, Designated Representative Karen Timberlake, Secretary Designee, DHS – Charles Warzecha, Deputy Designated Representative Charles Warzecha, Interim Administrator, DPH – Charles Warzecha, Deputy Designated Representative Preston Cole, Secretary, DNR – Greg Pils, Designated Representative Randy Romanski, Secretary Designee, DATCP – Gilbert (Gil) Kelley, Designated Representative James Morrison, Chair Greg Pils, Vice-Chair Jessica Blahnik, Member Jeffery Kindrai, Member Gina Green-Harris, Member Dr. German Gonzalez, Member Dr. Richard Moss. Member Dr. Robert Corliss, Member Charles Warzecha, Member Zana Sijan, DNR Alternate Steve Geis, DNR Alternate

- **FROM:** Dr. James Schauer, Secretary Director, Wisconsin State Laboratory of Hygiene
- RE: Wisconsin State Laboratory of Hygiene Board of Directors Meeting Wisconsin State Laboratory of Hygiene \*\*\*Online Meeting\*\*\* September 21, 2021, 1:00 p.m. — 3:00 p.m.

C:

Dr. Heather Barkholtz Allen Benson Cynda DeMontigny Kristine Hansbery Ann Hennings Kevin Karbowski Jan Klawitter Meshel Lange Dr. Errin Rider Dr. Martin Shafer Noel Stanton James Sterk Jr. Steve Strebel David Webb

# WISCONSIN STATE LABORATORY OF HYGIENE BOARD OF DIRECTORS

# **MEETING NOTICE**

Tuesday, September 21, 2021

1:00p.m. – 3:00p.m.

# MEETING LOCATION: Conference Line: 1(877) 336-1828 Access Code: 4271573

**Notice is hereby given** that the Wisconsin State Laboratory of Hygiene Board of Directors will convene at <u>1:00 p.m. on Tuesday, September 21, 2021</u> via teleconference.

**Notice is further given** that matters concerning Wisconsin State Laboratory of Hygiene issues, program responsibilities or operations specified in the Wisconsin Statutes, which arise after publication of this notice may be added to the agenda and publicly noticed no less than two hours before the scheduled board meeting if the board Chair determines that the matter is urgent.

**Notice is further given** that this meeting may be conducted partly or entirely by teleconference or videoconference.

**Notice is further given** that questions related to this notice, requests for special accommodations, or requests for a public appearance are addressed by the Wisconsin State Laboratory of Hygiene Administrative Offices by phone at (608) 890-0288 or in writing to the Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, Wisconsin, 53706.

# ORDER OF BUSINESS: See agenda.

Respectfully submitted,

Jak Schi

James J. Schauer, PhD, P.E., M.B.A. Secretary, Wisconsin State Laboratory of Hygiene Board of Directors Director, Wisconsin State Laboratory of Hygiene

# Wisconsin State Laboratory of Hygiene Board of Directors Meeting September 21, 2021 1:00 P.M. – 3:00 P.M.

# Wisconsin State Laboratory of Hygiene \*\*\*ONLINE MEETING\*\*\*

# AGENDA

# **PROCEDURAL ITEMS**

# PAGE

ltem 1.	ROLL CALL	4
ltem 2.	APPROVAL OF MINUTES	5
ltem 3.	REORGANIZATION OF AGENDA	12
ltem 4.	PUBLIC APPEARANCES	13
ltem 5.	BOARD MEMBERS' MATTERS	15

## **BUSINESS ITEMS**

ltem 6.	INTRODUCTION OF New WSLH Board Member JESSICA BLAHNIK	16
ltem 7.	LABORATORY IMPROVEMENT DIVISION PRESENTATION	17
ltem 8.	STRATEGIC PLAN UPDATE	18
	<ul> <li>DEI Initiative</li> <li>Space</li> <li>Human Biomonitoring</li> </ul>	
ltem 9.	FINANCIAL REPORT	19
ltem 10.	CONTRACTS REPORT	27
Item 11.	HR UPDATE	29
ltem 12.	DIRECTOR'S REPORT	31
	<ul> <li>Overview of Variant Dashboard</li> <li>Water Boil Notice Report</li> <li>Public Relations Report</li> </ul>	

# PROCEDURAL ITEMS

## Item 1. ROLL CALL

# Description of Item:

Roll call of attendance at Board Meeting led by Board Chair.

# Suggested Board Action:

Submit roll call.

# **Staff Recommendation and Comments:**

Roll call will be recorded by Board Secretary.

# PROCEDURAL ITEMS

#### Item 2. APPROVAL OF MINUTES

#### **Description of Item:**

The draft minutes of the June 22, 2021 board meeting are submitted for approval.

# **Suggested Board Action:**

Motion: Approve the draft minutes of the June 22, 2021 board meeting as submitted.

#### **Staff Recommendation and Comments:**

Approve draft minutes.

Once approved, minutes become part of the public record and are posted on the WSLH website: <u>http://www.slh.wisc.edu/about/board/board-meetings-agendas-and-minutes/</u>.

### **APPROVED MINUTES**

# June 22, 2021 1:00 P.M. – 3:00 P.M. Wisconsin State Laboratory of Hygiene 2601 Agriculture Drive Madison, WI 53718

MEMBERS PRESENT:	Chair James Morrison, Vice-Chair Greg Pils, Secretary Dr. James Schauer, Dr. German Gonzalez, Dr. Richard Moss, Barry Irmen, Greg Pils, Gil Kelley, Jeffery Kindrai
WSLH STAFF PRESENT:	Kevin Karbowski, Allen Benson, David Webb, Jan Klawitter, Dr. Errin Rider, James Sterk, Amy Miles, Dr. Kaitlin Sundling, Dr. Kelsey Florek, Noel Stanton, Kris Hansbery, and Nathaniel Javid
DNR STAFF PRESENT: GUESTS PRESENT:	Zana Sijan, Steve Geis Dr. Keith Poulsen

# Chair James Morrison made a motion to call the meeting to order at 1:00 P.M. Dr. Richard Moss seconded the motion. The meeting commenced at 1:00 P.M.

## Item 1. ROLL CALL

**Chair James Morrison** initiated the roll call of the Board. Nathaniel Javid conducted the roll call of the Board members. All Board Member seats or their designated representatives were present except Gina Green-Harris, Dr. Robert Corliss, and Charles Warzecha. There were no attendees on the public telephone line.

### Item 2. APPROVAL OF MINUTES

Approve the minutes of the March 23, 2021 Board Meeting as submitted. **Greg Pils** entertained a motion to approve the minutes. **Dr. Richard Moss** seconded the motion. The voice vote approving the minutes was unanimous.

### Item 3. REORGANIZATION OF AGENDA

There was no request to reorganize the agenda.

### Item 4. PUBLIC APPEARANCES

Keith Poulsen from the Wisconsin Veterinary Diagnostic Laboratory.

### Item 5. BOARD MEMBERS' MATTERS

There were no board member matters.

#### Item 6. BARRY IRMEN WSLH BOARD RETIREMENT

Chair James Morrison noted that Barry Irmen is retiring from serving on the Board of Directors after 17 years of service as a Dane County Medical Examiner. Mr. Morrison thanked Mr. Irmen for his service to the Board, and the people of Wisconsin. Mr. Irmen thanked the Board, Dr. Schauer, and the experts at the Wisconsin State Laboratory of Hygiene (WSLH) along with the service the WSLH has provided to the Coroners and Medical Examiners. Dr. Schauer thanked Mr. Irmen for his kind words and service.

### Item 7. STRATEGIC PLAN UPDATE

Dr. James Schauer highlighted the strategic initiatives for the Board including the new initiative of Diversity, Equity, and Inclusion, which is an important issue for public health, society, and UW-Madison. Dr. Schauer provided a brief overview of each initiative including Diversity, Equity and Inclusion, Outreach, Advancing the Public Health Mission of UW SMPH, Bioinformatics, Clinical Biomonitoring, Point of Care Testing, Scientific Investment, Modernization of LIMS, eGovernment, and Space Optimization. Diversity, Inclusion and Equity (DEI) will be led by WSLH Clinical Laboratory Director, Dr. Errin Rider. Since this is a new initiative, Year 1 goals and outcomes include providing formal DEI training for WSLH staff, performing an assessment of the laboratory environment, culture, and current practice, and engaging with the Association of Public Health Laboratories and University of Wisconsin-Madison DEI efforts. Also, WSLH leadership will continue to participate in DEI training and educational opportunities. Outreach will be led by Public Relations Manager, Jan Klawitter. The implementation strategy for Outreach will depend on the results of internal and external stakeholder input. Based on initial feedback to date, activities may include: training and educational videos, tutorials, and resources on the WSLH website, additional communication tools and resources, and expanded external stakeholder meetings, event outreach, and the WSLH Speakers Bureau. The Advancing the Public Health Mission initiative is led by WSLH Newborn Screening Co-Director, Dr. Mei Baker. The implementation strategy for this will focus on enhancing established partnerships and developing new partnerships between the WSLH and academic departments in SMPH. These including WSLH providing research seminars for SMPH, WSLH initiating research programs or services relevant to SPMH missions, WSLH faculty and staff strategically pursuing teaching opportunities in SMPH, and strategic hires for faculty with joint appointments at the WSLH and in SMPH departments. Bioinformatics will be led by Dr. Kelsey Florek with a capacity building focus on development of computer infrastructure to meet the demands of data analysis, developing a skilled workforce capable of designing and running bioinformatics strategies, and building an integrated data storage system. The Clinical Biomonitoring initiative is led by Noel Stanton. Implementation will focus on maintaining and expanding partnerships with entities supporting and engaging in biomonitoring activities, along with the expansion of testing capability. Important partners include but are not limited to: the National Biomonitoring Network, Society of Forensic Toxicologists, and the Lab Response Network, public health surveillance and research programs, population health, environmental toxicology, occupational medicine and other researchers. The Point of Care Testing (POCT) initiative is led by

Laboratory Improvement Division Director, Kris Hansbery. The WSLH can potentially fill several roles relating to this testing evolution including the provision of proficiency testing or characterized samples to help assure result reliability, delivery of training for users and serving as an objective technical resource for users. Also maintenance and loaning of field equipment for use by public health, safety, and natural resource partners. The Scientific Investment initiative is led by Dr. Mei Baker. WSLH Administration. Faculty and Research staff will work together to develop the programs for scientific investment. The WSLH Faculty and Scientist Committee will help direct these programs and help identify additional opportunities to advance scientific leadership within and across all WSLH divisions. The Modernization of LIMS strategic initiative is led by Office of Information Services (OIS) director, Allen Benson. The background and rationale for this is that LIMS software is critical to the successful recording and distribution of lab results within and outside of the lab. The following steps have been taken to ensure OIS can support and enhance the LIMS environment at the WSLH: Using open positions, OIS has created a team focused on supporting the various lab's configuration and usage needs of WSLH software systems (including LIMS). This has helped WSLH to share technical expertise, methods, and training across labs. OIS is developing improved support models for LIMS and LIMS admins. Mr. Benson also leads the eGovernment strategic initiative. Some ongoing efforts for this include configuring and rolling out LIMS Outreach features, building and enhancing data sharing interfaces with other government agencies, and building and enhancing data sharing interfaces with client organizations; for example, electronic lab report, web lab report, and electronic test orders and results. The last strategic initiative, Space, is led by WSLH Environmental Health Division Director, David Webb. Some existing and future needs include maintaining existing space to acceptable and high-guality standards, identifying new space to expand into or move a program or department or division to relive existing pressure such that space constraints do not hinder capability and capacity and increasing the extent to which the WSLH controls its space for cost, sustainability, backup and emergency needs.

After presenting the initiatives, Dr. Schauer noted that he will leave this up to the Board for their endorsement. Chair Jim Morrison said he is supportive of this strategic plan. **Jeffrey Kindrai** entertained a motion that he is OK with moving forward. **Dr. Richard Moss** seconded the motion. The strategic plan was approved by the Board. Dr. Schauer thanked the Board for their input and noted that the WSLH will keep the Board informed on the progress of the Strategic Plan. Plan.

# Item 8. FINANCIAL REPORT

### Kevin Karbowski, Chief Financial Officer, Wisconsin State Laboratory of Hygiene

Mr. Karbowski reviewed the Statement of Income for the period of July 1, 2020 through April 30, 2021 with the Board. He noted that we have a \$211,341 budgeted loss, with a year-to-date actual loss of \$810, 870. This significant difference is due in large part to inflation on supplies costs from COVID. Also, although we increased testing in some areas due to the pandemic, we also experienced areas of the lab with decreased testing. We also have not had a newborn screening card increase in more than eleven years. All of these factors combined explain the difference between the actual year-to-date loss and budgeted year-to-date loss. Mr. Karbowski had the Board refer to the packet for more details on the income statement. Next, Mr. Karbowski presented the working capital to the Board. Our working capital has decreased by \$2,142, 587 since June 30, 2020. Since our revenue has gone up, our operating contingency has also gone up. Of the \$2, 142, 587, we have a \$440, 103 increase in the reserve we need to hold, giving us a total working capital decrease of \$1,702, 484. About 82% of this decrease is due to the newborn screening card expenses and essential newborn screening equipment purchases needed to maintain program accreditation. The remaining decrease is due to various gains and losses. Mr. Kindrai asked Mr. Karbowski if these equipment purchases are planned or

unanticipated. Mr. Karbowski responded that these were planned and Dr. Schauer noted that we also will need to replace equipment once a vendor stops supporting it in order to maintain accreditation.

# Item 9. CONTRACTS REPORT

### Kevin Karbowski, Chief Financial Officer, Wisconsin State Laboratory of Hygiene

Mr. Karbowski provided the contracts summary since the last Board Meeting. The total amount of contracts signed over the last three months is \$1,603,002 in additional work, all with the WI Department of Health Services. Mr. Karbowski had the Board refer to the packet for additional details.

## Item 10. FY22 BUDGET APPROVAL

# Kevin Karbowski, Chief Financial Officer, Wisconsin State Laboratory of Hygiene

Dr. Schauer noted that although the losses are higher this year than we want, they are still within reason within the context of the pandemic and our \$60M per year budget. We have the reserves to cover this, but also want to make sure we are not depleting the reserves as we need this as part of our investment. This feeds into our plans for the FY22 budget. Mr. Karbowski presented the budget on both an accrual and cash basis. This year's budget presented a number of challenges with trying to break even. In this budget, we've assumed that our prices for supplies have not decreased. Proposed salary increases are also not reflected in this budget. We are expecting to ask the Board for a 4-6% price increase to help cover costs. Mr. Karbowski noted that we do not want to ask for more than we need, so we are not planning to ask for a price increase at this time. Dr. Schauer noted the growth of our lab in recent years with the volume of work with our revenues and expenses. We hope to grow even more next year. The loss from a cash point of view is pretty small relative to a \$60M budget. On an accrual basis, we have a loss of \$624,669 and on a cash basis we have a loss of \$108,710. Chair James Morrison noted that the price increase in newborn screening appears well justified. Chair James Morrison entertained a motion to approve the budget as presented, so moved by Jeffery Kindrai. German Gonzalez seconded the motion. The FY22 WSLH Budget was accepted by the Board.

### Item 11. HR UPDATE

# Cynda DeMontigny, HR Director, WSLH

Ms. DeMontigny provided the HR update to the Board. We had nineteen recruitments from the period of March 18 to June 11, 2021. There were four recruitments in both our Disease Prevention Division and Administration, five recruitments in both our Environmental Health Division and Communicable Disease Division, one recruitment in our Laboratory Improvement Division, and none in our Occupational Health Division. Ms. DeMontigny noted the hires, resignations, and retirements for this period as well. Overall, there were 24 hires, 7 resignations, and 4 retirements.

#### Item 12. DIRECTOR'S REPORT

#### Dr. Jamie Schauer, Director, WSLH

Dr. Allen Bateman, WSLH Communicable Disease Division Director, presented on COVID-19 testing and sequencing trends. Dr. Bateman presented graphs on new reported cases by day, hospitalizations, tests by day, and new reported deaths by day in the U.S. Dr. Bateman also presented data on new confirmed cases and percent positive by test cases in Wisconsin. Overall, we are at some of the lowest rates we've seen since March 2020. Dr. Bateman next reviewed some technologies for whole genome sequencing including MiSeq, MinION, NextSeq, and GridION. Dr. Bateman reviewed some of the applications of whole genome sequencing including tracking transmission, estimating the reproductive number, estimating the prevalence of infection, answering questions about individual use cases, tracking mutations, and detection of novel variants of concern. Dr. Bateman noted the work of WSLH Bioninformatician, Dr. Kelsey Florek in developing the Wisconsin SARS-CoV-2 Genomic Dashboard, which contains statewide variant information. Dr. Bateman included graphs on total sequences by county and time period. Also, Dr. Bateman presented a graph on the proportion of sequenced strains that are variants over time by sample collection date. Last, Dr. Bateman reviewed the national roles of WSLH CDD in SARS-CoV-2 testing and whole genome sequencing.

WSLH Assistant Director and Environmental Health Division Director, David Webb, provided an update on PFAS Testing and a summer workshop. Mr. Webb noted overall interest in PFAS continues to increase. The matrices that have become of interest lately are in serum, fish, water and air. We have developed and validated a method for PFAS in serum. This will hopefully give us a pretty good representation of PFAS in Wisconsin. There is a lot of federal interest in monitoring for PFAS. Part of the challenges in monitoring PFAS is developing the methods and matrices and examining new approaches. We are looking at new ways for measuring PFAS -- as there is so much interest -- but it is an expensive and complicated test. Pre-COVID, we planned to have a workshop about PFAS. Now, we are thinking again about having a WI based and research focused workshop led by the UW Aquatic Sciences Center to analyze data gaps and come up with a research agenda and address exposure, toxicology and measurement.

Next, Mr. Webb presented on space. We are experiencing a lot of growth and expansion in the lab. Examples of this include sequencing, surveillance, PFAS, Forensic Toxicology, the Soils Lab, and COVID in wastewater. We are looking at renovating, building, and leasing options and are seeing what we can do to make better use of our space in Stovall as parts of Stovall vacated over the years when labs moved to Ag Drive. There are a number of joint efforts with our state and UW partners and colleagues in figuring out how to make good use of existing resources and possible new ones.

Mr. Webb presented an update on the soils lab at the WSLH. This has been a great partnership and team effort with the UW College of Agriculture and Life Sciences. The Lab is currently in Marshfield, but we hope to occupy the Madison lab space in late September (Hill Farms). The Director has been hired and one chemist position is posted. Starting July 1st, the soils lab will be operating under the WSLH but it is currently still in Marshfield, WI. During the transition from Marshfield to Madison, we hope to minimize closure. Once the lab is operating and stabilized, we can discuss future services, innovation and agency partnerships.

Allen Benson, WSLH Office of Information Systems Director, presented to the Board on the relocation of WSLH servers to an off-site location, OneNeck Data Center. OneNeck is a DoIT leased and managed space. For this facility, the WSLH would be billed by UW Madison monthly (DoIT). This is a well-planned approach for tying us into DoIT along with providing us cost savings. This includes many benefits including fully redundant power and network provided, no locally hosted data center for much better flexibility, reduction in capital for data center

components, 24X7 support provided by OneNeck, expandable service as needed, and a secure facility with limited and controlled access to our equipment.

Dave Webb presented the water systems boil notice to the Board. There was one boil notice for Marinette County.

Jan Klawitter, WSLH Public Relations Manager, presented the WSLH recent events to the Board. These include the announcement of Dr. Heather Barkholtz joining the WSLH and the UW School of Pharmacy and Dr. Alana Sterkel as the new WSLH Communicable Disease Division Associate Director. Ms. Klawitter also highlighted events such as the virtual National Violent Death Report Systems meetings with US Congress members, the Wisconsin SARS-CoV-2 Genomic Dashboard, and the National Atmospheric Deposition Program Spring 2021 virtual meeting. Ms. Klawitter noted Emeritus WSLH Director Dr. Peter Shult received the APHL Lifetime Achievement Award. In early June, the DNR issued new advisories for PFAS fish consumption for the Yahara chain of lakes and waterways. This was very much a team effort between the WSLH and the DNR. Ms. Klawitter had the Board refer to the Board packet for more details.

**Chair James Morrison** made a motion to adjourn the meeting at 3:00 P.M. **Jeffery Kindrai** accepted the motion and **Barry Irmen** seconded the motion. The motion passed unanimously and the meeting was adjourned.

Respectfully submitted by:

Ja Ja Soli

James J. Schauer, PhD, P.E., M.B.A. Secretary, Wisconsin State Laboratory of Hygiene Board of Directors

# PROCEDURAL ITEMS

# Item 3. REORGANIZATION OF AGENDA

#### **Description of the Item:**

Board members may suggest changes in the order in which agenda items are discussed.

#### **Suggested Board Action:**

None.

# **Staff Recommendation and Comments:**

Reorganize the agenda if requested by the Board.

#### PROCEDURAL ITEMS

### Item 4. PUBLIC APPEARANCES

#### **Description of the Item:**

Under the board's *Policies and Procedures* nonmembers are invited to make presentations.

#### **Suggested Board Action:**

Follow WSLH Policies and Procedures.

#### **Staff Recommendation and Comments:**

Follow WSLH Policies and Procedures.

Per Policies and Procedures of the Wisconsin State Laboratory of Hygiene Board of Directors:

- §6.12 *Speaking privileges.* When the board is in session, no persons other than laboratory staff designated by the director shall be permitted to address the board except as hereinafter provided:
  - (a) A committee report may be presented by a committee member who is not a member of the board.
  - (b) A board or committee member in the course of presenting a matter to the board may request staff to assist in such a presentation.
  - (c) If a board member directs a technical question for clarification of a specific issue to a person not authorized in this section, the Chair may permit such a person to respond.
  - (d) The board may by majority vote or by decision of the Chair allow persons not otherwise authorized in this section to address the board if the situation warrants or the following criteria is followed:
    - (1) Written requests for public appearances on specific current agenda items shall be made to the board Secretary <u>no later than two working days</u> prior to the meetings. The request shall outline the reasons for the request including the subject matter to be discussed in as much detail as is feasible prior to the meeting of the board. Those requesting an appearance may, at or prior to the board meeting, provide board members copies of any written materials to be presented or a written statement of a position.
    - (2) Individual presentations will be limited to five minutes, unless otherwise authorized by the Chair.
    - (3) To schedule an appearance before the Wisconsin State Laboratory of Hygiene Board of Directors, contact the board Secretary, c/o Director, Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Madison, Wisconsin 53706. Telephone (608) 890-0288. The subject or subjects to be discussed must be identified.
    - (4) The Wisconsin State Laboratory of Hygiene "Guidelines for Citizen Participation in WSLH Board Meetings" are published on its website: http:// www.slh.wisc.edu/index.shtml and printed copies are available on request. (See Appendix 5) [Section §6.12 approved 5/27/03 board meeting.]

# Appendix 5

# **Guidelines for Citizen Participation at WSLH Board Meetings**

The Wisconsin State Laboratory of Hygiene board provides opportunities for citizens to appear before the board to provide information to the board on items listed on the agenda. Such appearances shall be brief and concise. In order to accommodate this participation in the allotted time, the guidelines are as follows:

- A. Items to be brought before the board:
  - 1. The board Secretary and Chair will assign a specific time on the agenda to hear public comment when a request to speak has been received from a member of the public.
  - Individuals or organizations will be limited to a total of five (5) minutes to make a
    presentation to the board. Following the presentation board members may ask clarifying
    questions.
  - 3. An organization is limited to one (1) spokesperson on an issue.
  - 4. On complex issues, individuals wishing to appear before the board are encouraged to submit written materials to the board Secretary in advance of the meeting so the board may be better informed on the subject in question. Such information should be submitted to the board Secretary for distribution to all board members <u>no later than seven (7) working days</u> before the board meeting.
  - 5. No matters that are in current litigation may be brought before the board.
- B. The board encourages individuals to confine their remarks to broad general policy issues rather than the day-to-day operations of the Wisconsin State Laboratory of Hygiene.
- C. Citizens who have questions for board members should ask these questions prior to the board meeting, during any recess during the board proceedings, or after board adjournment.
- D. Written requests to appear before the WSLH Board of Directors should be submitted <u>no</u> <u>later than two (2) working days</u> prior to a scheduled board meeting.
- E. Submit written requests to: Secretary, Wisconsin State Laboratory of Hygiene Board of Directors C/O WSLH Director 465 Henry Mall Madison, WI 53706 Telephone: (608) 890-0288 Email: <u>nathaniel.javid@slh.wisc.edu</u>

#### **BUSINESS ITEMS**

## Item 5. BOARD MEMBERS' MATTERS

#### **Description of the Item:**

Board Members' Matters will present board members with the opportunity to ask questions and/or discuss issues related to the Wisconsin State Laboratory of Hygiene.

# Suggested Board Action:

Receive for information.

# **Staff Recommendations and Comments:**

### **BUSINESS ITEMS**

# Item 6. INTRODUCTION OF New WSLH Board Member JESSICA BLAHNIK

# Description of the Item:

Jessica Blahnik, WSLH Board Medical Examiner's Office Representative succeeding Barry Irmen, will introduce herself to the Board.

# <u>Suggested Board Action:</u> Receive for information.

#### **Staff Recommendations and Comments:**

## **BUSINESS ITEMS**

# Item 7. LABORATORY IMPROVEMENT DIVISION PRESENTATION

#### **Description of the Item:**

Kristine Hansbery, WSLH Laboratory Improvement Division Director (LID), and Ann Hennings (LID) will present on SARS-CoV-2 and LID.

## **Suggested Board Action:**

Review and provide input.

# Staff Recommendations and Comments:

## **BUSINESS ITEMS**

# Item 8. STRATEGIC PLAN UPDATE

#### **Description of the Item:**

The Strategic Plan Update will consist of three presentations on the following:

- 1. DEI Initiative Dr. Errin Rider (WSLH)
- 2. Space David Webb (WSLH)
- 3. Human Biomonitoring Dr. Martin Shafer, Dr. Heather Barkholtz, Noel Stanton, Meshel Lange (WSLH)

# **Suggested Board Action:**

Review and provide input.

# **Staff Recommendations and Comments:**

## **BUSINESS ITEMS**

#### Item 9. FINANCIAL REPORT

## Description of the Item:

Kevin Karbowski, WSLH Chief Financial Officer, will provide the Financial Report to the Board.

# Suggested Board Action: Review and provide input.

## **Staff Recommendations and Comments:**

#### WISCONSIN STATE LABORATORY OF HYGIENE

#### FINANCIAL REPORT

FISCAL YEAR 2021

June 30, 2021

Contents

#### FINANCIAL STATEMENTS

Statement of income

Comparative income statement

Comparative balance sheet

Statement of cash flows

Notes to the financial statements

### WISCONSIN STATE LABORATORY OF HYGIENE STATEMENT OF INCOME For the period July 1, 2020 through June 30, 2021

	Fiscal Year 2021 Actual	Fiscal Year 2021 Budget	Variance Over/(Under)	Variance % of Budget
SUPPORT AND REVENUE				
Laboratory Services Revenues (Note 2)				
Department of Health Services	\$16,557,333	\$9,912,763	\$6,644,570	67.0%
Newborn Screening	4,400,257	4,500,000	(99,743)	-2.2%
Driver Improvement Surcharge (OWI)	1,619,200	1,619,200	0	0.0%
Department of Natural Resources	605,727	900,000	(294,273)	-32.7%
University of Wisconsin Systems	770,995	900,000	(129,005)	-14.3%
Other Wisconsin State and Local Agencies	330,564	332,863	(2,299)	-0.7%
Wisconsin State and Local Agencies	24,284,077	18,164,826	6,119,251	33.69%
Clinical	5,891,047	5,455,095	435,952	8.0%
Proficiency Testing	3,343,866	3,195,540	148,326	4.6%
Occupational Health	1,312,134	1,800,000	(487,866)	-27.1%
National Atmospheric Deposition Program	1,614,798	1,777,308	(162,510)	-9.1%
Association of Public Health Laboratories	552,060	1,107,233	(555,173)	-50.1%
Federal Agencies	260,525	234,546	25,979	11.1%
Environmental Testing	1,274,501	1,331,926	(57,425)	-4.3%
Other Nonagency	124,437	75,014	49,423	65.9%
Nonagency	14,373,368	14,976,662	(603,294)	-4.0%
Sponsored Projects	6,566,312	6,727,848	(161,536)	-2.4%
Earnings - Investment Income	6,185	56,000	(49,815)	-89.0%
Program Revenue	45,229,942	39,925,336	5,304,606	13.3%
State General Program Revenue (GPR)	11,673,379	11,900,000	(226,621)	-1.9%
TOTAL SUPPORT AND REVENUE	56,903,320	51,825,336	5,077,984	9.8%
EXPENSES				
Salaries	22,215,577	21,258,905	956,672	4.5%
Fringe Benefits	8,236,505	7,947,298	289,207	3.6%
Supplies & Services	20,080,055	16,449,982	3,630,073	22.1%
Transfer Overhead to UW	970,218	969,245	974	0.1%
Building Rent	3,181,641	3,212,567	(30,926)	-1.0%
Depreciation	2,026,375	2,183,999	(157,624)	-7.2%
Bad Debt Expense	1,751	6,000	(4,249)	-70.8%
Interest Expense	1,470	6,000	(4,530)	-75.5%
TOTAL EXPENSES	56,713,593	52,033,996	4,679,597	9.0%
NET OPERATING INCOME (LOSS)	\$189,728	(\$208,660)	\$398,388	-190.9%

#### WISCONSIN STATE LABORATORY OF HYGIENE COMPARATIVE INCOME STATEMENT For the 10 months ended June 30, 2021 and April 30, 2020

	Current Year Actual	Prior Year Actual	Variance Over/(Under)	Percentage Change
SUPPORT AND REVENUE				
Laboratory Services Revenues (Note 2)				
Department of Health Services	\$16,557,333	\$8,067,485	\$8,489,848	105.2%
Newborn Screening	4,400,257	4,504,937	(104,680)	-2.3%
Driver Improvement Surcharge (OWI)	1,619,200	1,619,200	0	0.0%
Department of Natural Resources	605,727	722,022	(116,295)	-16.1%
University of Wisconsin Systems	770,995	806,302	(35,307)	-4.4%
Other Wisconsin State and Local Agencies	330,564	333,648	(3,084)	-0.9%
Wisconsin State and Local Agencies	24,284,077	16,053,594	8,230,483	51.27%
Clinical	5,891,047	5,691,341	199,706	3.5%
Proficiency Testing	3,343,866	3,264,688	79,178	2.4%
Occupational Health	1,312,134	1,694,103	(381,969)	-22.5%
National Atmospheric Deposition Program	1,614,798	1,721,243	(106,445)	-6.2%
Association of Public Health Laboratories	552,060	1,058,306	(506,246)	-47.8%
Federal Agencies	260,525	410,552	(150,027)	-36.5%
Environmental Testing	1,274,501	1,354,943	(80,442)	-5.9%
Other Nonagency	124,437	83,191	41,246	49.6%
Nonagency	14,373,368	15,278,367	(904,999)	-5.9%
Sponsored Projects	6,566,312	6,806,283	(239,971)	-3.5%
Earnings - Investment Income	6,185	174,078	(167,893)	-96.4%
Program Revenue	45,229,942	38,312,322	6,917,620	18.1%
State General Program Revenue (GPR)	11,673,379	11,605,493	67,886	0.6%
TOTAL SUPPORT AND REVENUE	56,903,320	49,917,815	6,985,505	14.0%
EXPENSES				
Salaries	22,215,577	21,501,863	713,714	3.3%
Fringe Benefits	8,236,505	8,069,068	167,437	2.1%
Supplies & Services	20,080,055	16,492,949	3,587,106	21.7%
Transfer Overhead to UW	970,218	955,895	14,323	1.5%
Building Rent	3,181,641	3,160,227	21,414	0.7%
Depreciation	2,026,375	2,092,647	(66,272)	-3.2%
Bad Debt Expense	1,751	2,799	(1,048)	
Interest Expense	1,470	23,291	(21,821)	-93.7%
Loss From Disposal Of Assets	0	19,077	(19,077)	
TOTAL EXPENSES	56,713,593	52,317,816	4,395,777	8.4%
NET OPERATING INCOME (LOSS)	\$189,728	(\$2,400,001)	\$2,589,729	-107.9%

#### WISCONSIN STATE LABORATORY OF HYGIENE COMPARATIVE BALANCE SHEET As of June 30, 2021 and June 30, 2020

#### ASSETS

June 30, 221         June 30, 2221           Current ASSETS         Sec.536,967         \$9,056,018           Cash-restricted-newborn screening surcharge         696,529         987,595           Net accounts receivables (Note 3)         5,66,761         3,833,922           Other receivables         912,602         894,742           Inventories         39,107         41,433           Prepaid expenses         264,896         94,484           Total current assets         14,147,282         14,908,200           Equipment         33,123,260         30,029,713           Building improvements         6,878,228         6,878,228           Classets         12,076,159         11,008,988           Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES         So         SO         SO           Accounts payable         \$0         \$0         SO           Accounts payable         \$0         \$0         SO           Accounts payable         \$6,529         97,595         SO           Total net fixed absences (Note 4)         997,964         726,933           Proficiency testing deferred revenue         1	ASSETS		
Cash         \$6,536,987         \$9,056,018           Cash-restricted-newborn screening surcharge         666,929         987,595           Net accounts receivables         912,602         894,742           Inventories         39,107         41,439           Prepaid expenses         264,896         94,484           Total current assets         14,147,282         14,908,200           Equipment         33,123,260         30,029,713           Building improvements         6,878,228         6,678,228           40,001,488         36,907,941         Less accumulated depreciation         (27,925,329)         (25,898,953)           Total net fixed assets         12,076,159         11,008,988         Total Assets         \$26,223,442         \$25,917,188           LIABILITIES AND EQUITY         CURRENT LIABILITIES         Salaries and fringe benefits payable         \$0         \$0           Accrued expenses         0         78,194         1,026,983         1,270,23,293         1,28,23,391           Compensated absences (Note 4)         997,964         726,983         1,270,23,293         1,28,283           Compensated absences (Note 4)         997,964         726,983         1,270,23,293         1,24,24,999           Newborn screening surcharge payable         6,6		June 30, 2021	June 30, 2020
Cash-restricted-newborn screening surcharge         696,929         987,595           Net accounts receivables (Note 3)         5,696,761         3,833,922           Other receivables         912,602         894,742           Inventories         39,107         41,439           Prepaid expenses         264,896         94,844           Total current assets         14,147,282         14,908,200           EQUIPMENT AND BUILDING IMPROVEMENTS         6,876,228         6,878,228           Equipment         33,123,260         30,029,713           Building improvements         6,876,228         6,878,228           du,001,488         36,907,941         Less accumulated depreciation         (27,925,329)         (26,898,963)           Total net fixed assets         12,076,159         11,008,988         Total Assets         \$26,223,442         \$25,917,188           LIABILITIES         Sataries and fringe benefits payable         \$0         \$0         \$0           Accounts payable         \$0         \$0         \$0         \$0           Accounts payable         \$0         \$1,127,027         \$0           Newborn screening defered revenue         1,024,366         1,127,027           Newborn screening defered revenue         1,657,664         1,868,391 </td <td></td> <td>¢0 500 007</td> <td><b>#0.050.040</b></td>		¢0 500 007	<b>#0.050.040</b>
Net accounts receivables (Note 3)         5,696,761         3,833,922           Other receivables         912,602         894,742           Inventories         39,107         41,439           Prepaid expenses         264,896         94,484           Total current assets         14,147,282         14,908,200           EQUIPMENT AND BUILDING IMPROVEMENTS         5,676,1         3,831,922           Equipment         33,123,260         30,029,713           Building improvements         6,878,228         6,678,239           Class accumulated depreciation         (27,925,329)         (26,898,953)           Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$0         \$0         \$0           Accounts payable         \$0,22,419         \$1,192           Compensated absences (Note 4)         997,964         726,983			
Other receivables         912,602         894,742           Inventories         33,107         41,439           Prepaid expenses         264,896         94,484           Total current assets         14,147,282         14,908,200           Equipment         33,123,260         30,029,713           Building improvements         6,878,228         6,878,228           40,001,488         36,907,941           Less accumulated depreciation         (27,925,329)         (25,888,953)           Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES AND EQUITY         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$0         \$0         \$0           Deferred revenue         1,024,366         \$1,127,027           Newborn screening surcharge paya	<b>50</b>		
Inventories         39,107         41,439           Prepaid expenses         264,886         94,484           Total current assets         14,147,282         14,308,200           EQUIPMENT AND BUILDING IMPROVEMENTS         Equipment         33,123,260         30,029,713           Building improvements         6,878,228         6,878,228         6,878,228           40,001,488         36,907,941         Less accumulated depreciation         (27,925,329)         (25,689,653)           Total net fixed assets         12,076,159         11,008,988         Total Assets         \$26,223,442         \$25,917,188           LIABILITIES         Salaries and fringe benefits payable         \$0         \$0         \$0           Accounts payable         \$0,25,19         3,195         Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027         Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         6,96,929         987,595         Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391         Total Liabilities         7,784,770         7,668,244			
Prepaid expenses         264,896         94,484           Total current assets         14,147,282         14,908,200           EQUIPMENT AND BUILDING IMPROVEMENTS         5         33,123,260         30,029,713           Building improvements         6,878,228         6,878,228         6,878,228           40,001,488         36,907,941         Less accumulated depreciation         (27,925,329)         (25,898,953)           Total net fixed assets         12,076,159         11,008,988         Total Assets         \$26,223,442         \$25,917,188           LIABILITIES         Salaries and fringe benefits payable         \$0         \$0         \$0           Accrued expenses         0         \$11,008,988         \$0         \$0           Accrued expenses         0         \$25,619         3,195         \$0           Compensated absences (Note 4)         997,964         726,983         \$195           Proficiency testing deferred revenue         2,310,120         2,424,999         \$242,499           Newborn screening deferred revenue         2,310,120         2,424,999         \$26,929         \$967,555           Total current liabilities         6,127,106         5,799,853         \$100F         \$1,657,664         1,868,391         \$1,612,7027           Newb			
Total current assets         14,147,282         14,908,200           EQUIPMENT AND BUILDING IMPROVEMENTS         33,123,260         30,029,713           Equipment         33,123,260         30,029,713           Building improvements         6,878,228         6,878,228           40,001,488         36,907,941           Less accumulated depreciation         (27,925,329)         (25,898,953)           Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$45,108         451,860           Accounts payable         845,108         1,27,027           Newborn screening deferred revenue         1,024,366         1,27,027           Newborn screening surcharge payable         6,96,929         987,595           Total current liabilities			
EQUIPMENT AND BUILDING IMPROVEMENTS           Equipment         33,123,260         30,029,713           Building improvements         6,878,228         6,878,228           40,001,488         36,907,941           Less accumulated depreciation         (27,925,329)         (25,898,953)           Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$0         \$0         \$0           Accounts payable         8445,108         451,860           Accounts payable         845,108         451,860           Accounts payable         \$0         \$0           Accounts payable         \$04,726,983         Proficiency testing deferred revenue           1,024,366         1,127,027         Newborn screening deferred revenue         1,024,366           Proficiency testing deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         6,96,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         2         2,693,484         2,253,381	· · · · ·		· · · · · · · · · · · · · · · · · · ·
Equipment         33,123,260         30,029,713           Building improvements         6,878,228         6,878,228           40,001,488         36,907,941           Less accumulated depreciation         (27,925,329)         (25,898,963)           Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES AND EQUITY         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$0         \$0         \$0           Accounts payable         \$0         \$0         \$0           Accounts payable         \$0         \$1,94         \$1,860           Accrued expenses         0         78,194         \$26,23,442         \$22,619         \$1,95           Compensated absences (Note 4)         997,964         726,983         \$108         \$1,127,027           Newborn screening deferred revenue         2,340,120         2,424,999         \$86,929         \$987,595           Total current liabilities         6,127,106         5,799,853         \$100         \$6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391         \$10 tal insetincted retained earnings	Total current assets	14,147,282	14,908,200
Building improvements         6,878,228         6,878,228         6,878,228         6,878,228         40,001,488         36,907,941           Less accumulated depreciation         (27,925,329)         (25,898,953)         Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$45,108         451,860         451,860           Accounts payable         \$0         78,194         Deferred revenue         252,619         3,195           Compensated absences (Note 4)         997,964         726,983         Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening deferred revenue         2,310,120         2,424,999         Newborn screening surcharge payable         6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391         Total Liabilities         7,784,770         7,668,244           EQUITY         Retained earnings-restricted (Note 5)         0perating contingency         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)         3,634,516         5,634,516	EQUIPMENT AND BUILDING IMPROVEMENTS		
40,001,488         36,907,941           Less accumulated depreciation         (27,925,329)         (25,898,953)           Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES AND EQUITY         CURRENT LIABILITIES         \$0         \$0           Salaries and fringe benefits payable         \$0         \$0         \$0           Accounts payable         \$0         \$1,860         \$45,108         451,860           Accourde expenses         0         78,194         \$252,619         3,195           Compensated absences (Note 4)         997,964         726,983         \$27,027           Newborn screening deferred revenue         1,024,366         1,127,027           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391           Total liabilities         7,784,770         7,668,244         EQUITY           Retained earnings-restricted (Note 5)         Coperating contingency         2,693,484         2,253,381           Net Operating lncome (Loss)         189,728         (2,400,000)<	Equipment	33,123,260	30,029,713
Less accumulated depreciation         (27,925,329)         (25,898,953)           Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES AND EQUITY         Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$45,108         451,860           Accounts payable         \$26,223,442         \$22,917,188           Deferred revenue         \$0         \$0           Accounts payable         \$45,108         451,860           Accounts payable         \$45,108         451,860           Accounts payable         \$0         78,194           Deferred revenue         \$22,619         3,195           Compensated absences (Note 4)         \$97,964         726,983           Proficiency testing deferred revenue         \$2,310,120         \$2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         1,657,664         1,868,391           Total liabilities         7,784,770         7,668,244           EQUITY         2,693,484         2,253,381           Net Operating lnco	Building improvements	6,878,228	6,878,228
Total net fixed assets         12,076,159         11,008,988           Total Assets         \$26,223,442         \$25,917,188           LIABILITIES AND EQUITY         Solaries and fringe benefits payable         \$0         \$0           Accounts payable         \$0         \$0         \$0           Accounts payable         \$451,860         Accounts payable         \$451,860           Accounts payable         \$0         78,194         Deferred revenue         225,619         3,195           Compensated absences (Note 4)         997,964         726,983         Proficiency testing deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         6,127,106         5,799,853         LONG TERM DEBT           Compensated Absences (Note 4)         1,657,664         1,868,391         Total liabilities         7,784,770         7,668,244           EQUITY         Retained earnings -restricted (Note 5)         Operating contingency         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)         Retained earnings -threstricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516         5,634,516         5,634,516         5,634,516         5,634,516		40,001,488	36,907,941
Total Assets         \$26,223,442         \$25,917,188           LIABILITIES AND EQUITY         CURRENT LIABILITIES         \$0         \$0           Salaries and fringe benefits payable         \$0         \$0         \$0           Accounts payable         845,108         451,860           Accounts payable         845,108         451,860           Accrued expenses         0         78,194           Deferred revenue         252,619         3,195           Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening surcharge payable         696,929         987,595           Total Current liabilities         6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391         Total Liabilities         7,784,770         7,668,244           EQUITY         Retained earnings-restricted (Note 5)         Operating contingency         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381         Soff,484         2,253,381           Net Operating Income (Loss)         <	Less accumulated depreciation	(27,925,329)	(25,898,953)
LIABILITIES AND EQUITY           CURRENT LIABILITIES           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         \$45,108         451,860           Accured expenses         0         78,194           Deferred revenue         252,619         3,195           Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391         Total long term debt         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391         Total Liabilities         7,784,770         7,668,244           EQUITY         Retained earnings-restricted (Note 5)         Operating contingency         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)         Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516<	Total net fixed assets	12,076,159	11,008,988
CURRENT LIABILITIES           Salaries and fringe benefits payable         \$0         \$0           Accounts payable         845,108         451,860           Accrued expenses         0         78,194           Deferred revenue         252,619         3,195           Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391         Total liabilities           Total long term debt         1,657,664         1,868,391         Total Liabilities           Total liabilities         7,784,770         7,668,244         EQUITY           Retained earnings-restricted (Note 5)         Operating ncome (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047         5,634,516         5,634,516           Total unrestricted retained	Total Assets	\$26,223,442	\$25,917,188
Salaries and fringe benefits payable         \$0         \$0           Accounts payable         845,108         451,860           Accrued expenses         0         78,194           Deferred revenue         252,619         3,195           Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391           Total long term debt         2,253,381         1           Total long term debt         1,657,664         2,253,381           Total restricted retained earnings         2,693,484         2,253,381           Net Operating ncome (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516	LIABILITIES AND EQUITY		
Salaries and fringe benefits payable         \$0         \$0           Accounts payable         845,108         451,860           Accrued expenses         0         78,194           Deferred revenue         252,619         3,195           Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391           Total long term debt         2,253,381         1           Total long term debt         1,657,664         2,253,381           Total restricted retained earnings         2,693,484         2,253,381           Net Operating ncome (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516			
Accounts payable       845,108       451,860         Accrued expenses       0       78,194         Deferred revenue       252,619       3,195         Compensated absences (Note 4)       997,964       726,983         Proficiency testing deferred revenue       1,024,366       1,127,027         Newborn screening deferred revenue       2,310,120       2,424,999         Newborn screening surcharge payable       696,929       987,595         Total current liabilities       6,127,106       5,799,853         LONG TERM DEBT       Compensated Absences (Note 4)       1,657,664       1,868,391         Total long term debt       1,657,664       1,868,391         Total Liabilities       7,784,770       7,668,244         EQUITY       Retained earnings-restricted (Note 5)       0         Operating contingency       2,693,484       2,253,381         Total restricted retained earnings       2,693,484       2,253,381         Net Operating Income (Loss)       189,728       (2,400,000)         Retained earnings-unrestricted       9,920,944       12,761,047         Contributed capital       5,634,516       5,634,516         Total unrestricted retained earnings       15,745,188       15,995,563         Total unrestric		¢۵	ድበ
Accrued expenses         0         78,194           Deferred revenue         252,619         3,195           Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391         Total Liabilities           Total long term debt         1,657,664         1,868,391         Total Liabilities           EQUITY         Retained earnings-restricted (Note 5)         Operating contingency         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381         State 12,761,047           Contributed capital         5,634,516         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total unrestricted retained earnings         15,745,188         15,995,563           Total unrestricted retained ear			
Deferred revenue         252,619         3,195           Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         0         1,657,664         1,868,391           Compensated Absences (Note 4)         1,657,664         1,868,391         1           Total long term debt         1,257,664         1,868,391         1           Total long term debt         1,657,664         1,868,391         1           Total long term debt         1,253,381         1         2,253,381           Total restric			
Compensated absences (Note 4)         997,964         726,983           Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         0         1,657,664         1,868,391           Compensated Absences (Note 4)         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391           Total long term debt         2,693,484         2,253,381           Retained earnings-restricted (Note 5)         0perating contingency         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)         89,920,944         12,761,047           Retained earnings-unrestricted         9,920,944         12,761,047         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563         15,995,563           Total unrestricted retained earnings         15,745,188         15,995,563           Total unrestricted retained earnings<	-	-	
Proficiency testing deferred revenue         1,024,366         1,127,027           Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         Compensated Absences (Note 4)         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391         1           Total liabilities         7,784,770         7,668,244           EQUITY         Retained earnings-restricted (Note 5)         0         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381         1           Net Operating Income (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944			
Newborn screening deferred revenue         2,310,120         2,424,999           Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         0         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391         1,657,664         1,868,391           Total Liabilities         7,784,770         7,668,244         1,657,664         1,868,391           EQUITY         Retained earnings-restricted (Note 5)         0perating contingency         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381         12,761,047           Net Operating Income (Loss)         189,728         (2,400,000)         12,761,047           Retained earnings-unrestricted         9,920,944         12,761,047         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563         15,995,563         16,248,944			
Newborn screening surcharge payable         696,929         987,595           Total current liabilities         6,127,106         5,799,853           LONG TERM DEBT         1,657,664         1,868,391           Compensated Absences (Note 4)         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391           Total Liabilities         7,784,770         7,668,244           EQUITY         Retained earnings-restricted (Note 5)         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total unrestricted retained earnings         15,745,188         15,995,563			
Total current liabilities       6,127,106       5,799,853         LONG TERM DEBT       1,657,664       1,868,391         Total long term debt       1,657,664       1,868,391         Total long term debt       1,657,664       1,868,391         Total Liabilities       7,784,770       7,668,244         EQUITY       Retained earnings-restricted (Note 5)       0perating contingency       2,693,484       2,253,381         Total restricted retained earnings       2,693,484       2,253,381       189,728       (2,400,000)         Retained earnings-unrestricted       9,920,944       12,761,047       5,634,516       5,634,516         Total unrestricted retained earnings       15,745,188       15,995,563       18,438,672       18,248,944	-		
LONG TERM DEBT       1,657,664       1,868,391         Compensated Absences (Note 4)       1,657,664       1,868,391         Total long term debt       1,657,664       1,868,391         Total Liabilities       7,784,770       7,668,244         EQUITY       Retained earnings-restricted (Note 5)       0perating contingency       2,693,484       2,253,381         Total restricted retained earnings       2,693,484       2,253,381       1000000         Net Operating Income (Loss)       189,728       (2,400,000)         Retained earnings-unrestricted       9,920,944       12,761,047         Contributed capital       5,634,516       5,634,516         Total unrestricted retained earnings       15,745,188       15,995,563         Total Equity       18,438,672       18,248,944	Newdorn screening surcharge payable	696,929	987,595
Compensated Absences (Note 4)         1,657,664         1,868,391           Total long term debt         1,657,664         1,868,391           Total Liabilities         7,784,770         7,668,244           EQUITY         Retained earnings-restricted (Note 5)         0           Operating contingency         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944	Total current liabilities	6,127,106	5,799,853
Total long term debt       1,657,664       1,868,391         Total Liabilities       7,784,770       7,668,244         EQUITY       Retained earnings-restricted (Note 5)       0         Operating contingency       2,693,484       2,253,381         Total restricted retained earnings       2,693,484       2,253,381         Net Operating Income (Loss)       189,728       (2,400,000)         Retained earnings-unrestricted       9,920,944       12,761,047         Contributed capital       5,634,516       5,634,516         Total unrestricted retained earnings       15,745,188       15,995,563         Total Equity       18,438,672       18,248,944	LONG TERM DEBT		
Total Liabilities         7,784,770         7,668,244           EQUITY         Retained earnings-restricted (Note 5)         2,693,484         2,253,381           Operating contingency         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944	Compensated Absences (Note 4)	1,657,664	1,868,391
Total Liabilities         7,784,770         7,668,244           EQUITY         Retained earnings-restricted (Note 5)         2,693,484         2,253,381           Operating contingency         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944	Total long term debt	1,657,664	1,868,391
EQUITYRetained earnings-restricted (Note 5)Operating contingency2,693,484Total restricted retained earnings2,693,4842,693,4842,253,381Net Operating Income (Loss)189,728Retained earnings-unrestricted9,920,94412,761,047Contributed capital5,634,516Total unrestricted retained earnings15,745,18815,995,56318,438,672Total Equity18,438,672	Total Liabilities		7 668 244
Retained earnings-restricted (Note 5)         Operating contingency       2,693,484       2,253,381         Total restricted retained earnings       2,693,484       2,253,381         Net Operating Income (Loss)       189,728       (2,400,000)         Retained earnings-unrestricted       9,920,944       12,761,047         Contributed capital       5,634,516       5,634,516         Total unrestricted retained earnings       15,745,188       15,995,563         Total Equity       18,438,672       18,248,944	=	1,101,110	1,000,211
Operating contingency         2,693,484         2,253,381           Total restricted retained earnings         2,693,484         2,253,381           Net Operating Income (Loss)         189,728         (2,400,000)           Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944	EQUITY		
Total restricted retained earnings       2,693,484       2,253,381         Net Operating Income (Loss)       189,728       (2,400,000)         Retained earnings-unrestricted       9,920,944       12,761,047         Contributed capital       5,634,516       5,634,516         Total unrestricted retained earnings       15,745,188       15,995,563         Total Equity       18,438,672       18,248,944	Retained earnings-restricted (Note 5)		
Net Operating Income (Loss)       189,728       (2,400,000)         Retained earnings-unrestricted       9,920,944       12,761,047         Contributed capital       5,634,516       5,634,516         Total unrestricted retained earnings       15,745,188       15,995,563         Total Equity       18,438,672       18,248,944	Operating contingency	2,693,484	2,253,381
Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944	- Total restricted retained earnings	2,693,484	2,253,381
Retained earnings-unrestricted         9,920,944         12,761,047           Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944	Not Operating Iscome (Loca)	400 700	
Contributed capital         5,634,516         5,634,516           Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944			
Total unrestricted retained earnings         15,745,188         15,995,563           Total Equity         18,438,672         18,248,944	-		
Total Equity         18,438,672         18,248,944		5,634,516	5,634,516
	Total unrestricted retained earnings	15,745,188	15,995,563
Total Liabilities and Equity         \$26,223,442         \$25,917,188	Total Equity	18,438,672	18,248,944
	Total Liabilities and Equity	\$26,223,442	\$25,917,188

23

# WISCONSIN STATE LABORATORY OF HYGIENE STATEMENT OF CASH FLOWS

#### For the 12 months ended June 30, 2021 and June 30, 2020

	Current Year	Prior Year
CASH FLOWS FROM OPERATING ACTIVITIES		
Net income	\$189,728	(\$2,400,000)
Adjustments to reconcile net income to net cash provided by operating		
activities:		
Depreciation	2,026,375	2,092,647
Changes in working capital components:		
Decrease/(Increase) in net accounts receivables	(1,862,839)	232,038
Decrease/(Increase) in other receivables	(17,860)	(38,107)
Decrease/(Increase) in inventories	2,332	12,529
Decrease/(Increase) in prepaid expenses	(170,412)	(12,542)
(Decrease)/Increase in salaries payable	0	0
(Decrease)/Increase in accounts payable	393,248	(522,642)
(Decrease)Increase in accrued expenses	(78,194)	(123,607)
(Decrease)Increase in deferred revenue	249,424	3,195
Decrease)Increase in proficiency testing deferred revenue	(102,661)	(57,939)
(Decrease)/Increase in newborn screen deferred revenue	(114,879)	1,300
(Decrease)/Increase in newborn screening surcharge payable	(290,666)	(577,017)
Net cash provided (used) in operating activities	223,597	(1,390,145)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of equipment and physical plant improvements	(3,033,294)	(1,953,209)
Net cash provided (used) in investing activities	(3,033,294)	(1,953,209)
CASH FLOWS FROM FINANCING ACTIVITIES		
Principal payment on Capital Lease		-
Net cash provided (used) in financing activities	<u> </u>	
Net increase (decrease) in cash	(2,809,697)	(3,343,354)
Cash:		
Beginning	10,043,613	13,386,967
Ending	\$7,233,916	\$10,043,613

#### WISCONSIN STATE LABORATORY OF HYGIENE NOTES TO THE FINANCIAL STATEMENTS For the period July 1, 2020 through June 30, 2021

#### NOTE 1 - NATURE OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

#### Nature of Business:

The Wisconsin State Laboratory of Hygiene (WSLH) is a governmental institution which provides medical, industrial and environmental laboratory testing and related services to individuals, private and public agencies, including the Department of Natural Resources (DNR) and the Department of Health Services (DHS). Approximately 75% of the WSLH operating revenues are program revenues, including contracts, grants, and fee-for-service billing. The remainder are general purpose revenues (GPR), which are Wisconsin state general fund dollars.

#### **Budgetary Data:**

- Fiscal Year 2020-2021 operating budget amounts were approved by the WSLH Board on June 16, 2020.

#### Basis of Presentation:

- The financial statements have been prepared on a modified accrual basis following Generally Accepted Accounting Principles (GAAP).

#### Basis of Accounting:

- Revenues are recognized at the completion of the revenue generating processes. Fee-forservice revenues are generally recognized in the period services are completed.
- Revenues from GPR, OWI, Grants, and expense reimbursement contracts for salaries, fringe benefits, capital, and supplies are recognized as expended.
- Expenses are recognized and accrued when the liability is incurred.

#### Estimates and assumptions:

- The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying footnotes. Actual results could differ from those estimates.

#### Assets:

- Cash is considered restricted if, by prior agreement with an outside entity, it must be segregated for future use by the outside entity or by WSLH at the outside entity's behest. As of June 30, 2021 available cash is restricted in an amount equal to the newborn screening surcharge payable to the Wisconsin Department of Health Services.
- Accounts receivable are reported at net realizable value. Net realizable value is equal to the gross amount of receivables less an estimated allowance for uncollectible amounts.
- Inventory is stated at cost (first in, first-out method).
- Equipment and building improvements are carried at cost. Expenditures for assets in excess of \$5,000 are capitalized. Depreciation is computed by the straight-line method.

#### Liabilities

A liability for unearned revenue is recognized for prepaid receipts for WSLH-provided Proficiency Testing programs and for prepaid newborn screening tests.

#### **NOTE 2 - LABORATORY SERVICES REVENUES**

At the Board's request, Laboratory Service Revenues on the Income Statement have been divided into two groups, Agency and Non-Agency, as follows:

#### Agency:

**Department of Health Services** Newborn Screening Driver Improvement Surcharge (OWI) **Department of Natural Resources** University of Wisconsin Systems **Municipalities** Law Enforcement Agencies Department of Agriculture, Trade and Consumer Protection Office of Justice Assistance Wisconsin Emergency Management Non-Agency: UW Hospital Authority Medicare and Medicaid **Proficiency Testing Occupational Health Federal Agencies** All other revenue from individuals, businesses, clinics, and hospitals,

#### NOTE 3 - ACCOUNTS RECEIVABLE

Accounts receivable and allowance for uncollectible account balances as of April 30, 2021 and June 30, 2020 are as follows:

	<u>June, 30, 2021</u>	<u>June 30, 2020</u>
Accounts Receivable Total	\$5,786,045	\$3,932,433
Allowance for bad debt	(89,284)	(98,511)
Net Receivables	\$5,696,761	\$3,833,922

#### **NOTE 4 - COMPENSATED ABSENCES**

- GASB Statement No. 16, "Accounting for Compensated Absences," establishes standards of accounting and reporting for compensated absences by state and local governmental entities for which employees will be paid such as vacation, sick leave, and sabbatical leave. Using the criteria in Statement 16, a liability for compensated absences that is attributable to services already rendered and that is not contingent on a specific event that is outside the control of the State and its employees has been accrued. The table below details the liability by benefit category:

				Legal	
	Total	Vacation	Pers Hol	Hol	Sabbatical
Current	\$997,964	\$817.902	\$74,036	\$3,400	\$102,626
Long					
Term	1,657,664				1,657,664
	\$2,655,628	\$817,902	\$74,036	\$3,400	\$1,760,290

#### NOTE 5 - RETAINED EARNINGS - RESTRICTED

The operating contingency is computed annually and reflects two months of salary and fringe benefit cost for positions funded from program revenues. The contingency fund is considered adequately funded if working capital is greater than the contingency fund restriction. As of June 30, 2021 working capital (current assets less current liabilities) was \$8,020,176 thereby meeting the target contingency reserve requirement of \$2,693,484.

# **BUSINESS ITEMS**

### Item 10. CONTRACTS REPORT

#### **Description of the Item:**

Kevin Karbowski, WSLH Chief Financial Officer, will provide the Contracts Report to the Board.

# **Suggested Board Action:**

Review and provide input.

# **Staff Recommendations and Comments:**

University of Wisconsin - Madison Wisconsin State Laboratory of Hygiene Summary of Contracts Executed Since March 2021 Board Meeting

		Award	
Title	Party	Amount Time	eframe Notes:
Epidemiology & Lab Capacity	WDHS	\$ 1,030,000 over 12	12 mos. Capacity & Preparedness for Emerging Infectious Diseases
Epidemiology & Lab Capacity	WDHS	266,000 over 12	12 mos. Capacity & Preparedness for Emerging Infectious Diseases
Reproductive Health	WDHS	121,500 over 12	2 mos. Reproductive Health & Family Planning Activities
TB 2021	WDHS	113,902 over 12	12 mos. TB Testing & Diagnostics
STI 2021	WDHS	71,600 over 12	12 mos. STI Test Kit Purchasing & Supply
		\$ 1,603,002	

#### **BUSINESS ITEMS**

# Item 11. HUMAN RESOURCES REPORT


# Description of the Item:


Cynda DeMontigny, WSLH Human Resources Director, will provide the HR update from the period of June 12 to September 10, 2021 to the Board.

## **Suggested Board Action:**

Receive for information.


# **Staff Recommendations and Comments:**





Recruitments						
June 12, 20	21 to September 10, 2021					
DPD	3					
EHD	5					
LID	0					
CDD	3					
Admin	2					
OHD	0					

*Resignations* June 12, 2021 to September 10, 2021



- AS Acad Staff
- US Univ Staff
- SH Student Hourly
- FT Faculty
- LTE Limited Term

# **BUSINESS ITEMS**

## Item 12. DIRECTOR'S REPORT

- a) Dr. James Schauer, Director, WSLH
  - Overview of Variant Dashboard
  - Water Boil Notice Report
  - Public Relations Report

# Report to the Wisconsin State Laboratory of Hygiene Board Water Systems Tests by the WSLH

# **June 1 – September 1, 2021**

COUNTY_NAME	PWS_TYPE	NUMBER_OF_SYSTEMS	NUMBER_OF_UNSAFE	NUMBER_OF_BWO
Door	TN	272	13	1

# Report to the Wisconsin State Laboratory of Hygiene Board

# Representative Public or Environmental Health Incidents of Educational Interest June 10 – September 10, 2021

Approx. Date	Agent or Event Name	Description	Current Status
	Name	OUTBREAKS and INCIDENTS	Status
January 2020	COVID-19 virus	<ul> <li>In early March, only the WSLH and the City of Milwaukee Health Dept. Lab were testing for COVID-19 virus in the state. Since then the WSLH has helped bring 130+ labs in the state online for testing and also added multiple different testing platforms. The WSLH continues to perform testing primarily in our outbreak response role.</li> <li>The WSLH continues to collaborate with the Wisconsin Veterinary Diagnostic Laboratory (WVDL) and University Health Services to maintain COVID testing at WVDL on the UW- Madison campus for UW students, faculty and staff.</li> <li>With funding from the WI Department of Health Services, the WSLH is also performing population-based surveillance testing.</li> <li>The WSLH Communicable Disease Division is performing antibody testing for the Past Antibody COVID-19 Community Survey (PACCS).</li> <li>WSLH Environmental Microbiology have developed methods and are performing testing for a statewide (and UW-Madison campus) wastewater surveillance study.</li> <li>The WSLH Communicable Disease Division is performing whole-genome sequencing of SARS- CoV-2 viruses for strain surveillance and variant detection statewide, as well as to inform many outbreaks, including outbreaks at mink farms and in Corrections facilities. The Division is also coordinating a network of 4 other labs in the</li> </ul>	Ongoing

		state that perform whole-genome sequencing for variant detection. With CARES/ELC funding through WI DHS, WisCon has established a <b>COVID-19 Consulting</b> <b>service, providing consultation services for WI</b> <b>businesses</b> seeking to improve their facility's employee protection plans and procedures related to COVID-19. The group is conducting bi- weekly public outreach webinars, provides phone and virtual consultation services. The services have been popular and well-received by served businesses and local public health departments around the state. Additionally, the group is partnering with DHS Procurement and Infection Preventionists to provide <b>respirator fit</b> <b>testing kits, training, and related assistance</b> to employees at over 4,500 nursing and residential care facilities throughout the state.	
		RECENT EVENTS and FINDINGS	
Spring- Summer 2021	Assorted Peer- Reviewed Journal publications	Several WSLH staff (names bolded) have published research in the past several months. <u>Forensic Toxicology</u> Comparison of Breath and Blood Alcohol Concentrations in a Controlled Drinking Study <i>Journal of Analytical Toxicology</i> , Published July 28, 2021, https://doi.org/10.1093/jat/bkab086 Lindsey Skaggs, Amy Heizler, Diane Kalscheur, Amy Miles, Heather M Barkholtz Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities—2021 Update <i>Journal of Analytical Toxicology</i> , Volume 45, Issue 6, July 2021, Pages 529–536, https://doi.org/10.1093/jat/bkab064 Amanda L D'Orazio, Amanda L.A Mohr, Ayako Chan-Hosokawa, Curt Harper, Marilyn A Huestis, Jennifer F Limoges, Amy K Miles, Colleen E Scarneo, Sarah Kerrigan, Laura J Liddicoat, Karen S Scott, Barry K Logan	Complete

# **Newborn Screening**

Newborn Screening for Spinal Muscular Atrophy: the Wisconsin First Year Experience Neuromuscular Disorders, Published July 27,

2021,

https://doi.org/10.1016/j.nmd.2021.07.398

Mei W. Baker, Sean T. Mochal, Sandra J. Dawe, Amy E. Wiberley-Bradford, Michael F. Cogley, Bethany R. Zeitler, Zachary D. Piro, Mathew M. Harmelink, Jennifer M. Kwon

Newborn Screening for Severe Combined Immunodeficiency Using the Multiple of the Median Values of T-Cell Receptor Excision Circles

International Journal of Newborn Screening, 2021, 7(3), 43; https://doi.org/10.3390/ijns7030043

Michael F. Cogley, Amy E. Wiberley-Bradford,

Sean T. Mochal, Sandra J. Dawe, Zachary D. Piro and Mei W. Baker

Newborn Screening for Severe Combined Immunodeficiency: Do Preterm Infants Require Special Consideration?

International Journal of Newborn Screening, 2021, 7(3), 40;

https://doi.org/10.3390/ijns7030040

Anne E. Atkins, Michael F. Cogley, Mei W. Baker

# Thyroid Hormone Function in Small for Gestational Age Term Newborns

*The Journal of Pediatrics,* Published June 29, 2021,

https://doi.org/10.1016/j.jpeds.2021.06.067

Dinushan C. Kaluarachchi, Victoria B. Nicksic, David B. Allen, Jens C. Eickhoff, **Mei W. Baker**, Pamela J. Kling

I	
	Newborn Screening for Severe Combined
	Immunodeficiency: 10-Year Experience at a
	Single Referral Center (2009–2018)
	Journal of Clinical Immunology, volume 41, pages
	595–602 (2021);
	https://doi.org/10.1007/s10875-020-00956-7
	Julia Thorsen, Kayla Kolbert, Avni Joshi, <b>Mei</b>
	Baker and Christine M. Seroogy
	Communicable Disease
	Performance of Repeat BinaxNOW Severe Acute
	Respiratory Syndrome Coronavirus 2 Antigen
	Testing in a Community Setting, Wisconsin,
	November 2020–December 2020
	Clinical Infectious Diseases, Volume 73, Issue
	Supplement_1, 15 July 2021, Pages S54–S57,
	https://doi.org/10.1093/cid/ciab309
	Melisa M Shah, et al (including Alana Sterkel,
	Allen Bateman)
	Description of a University COVID-19 Outbreak
	and Interventions to Disrupt Transmission,
	Wisconsin, August – October 2020. Emerging
	Infectious Diseases. 2021. In press. Currie D, et al
	(including Allen Bateman).
	Evidence of Early Household Transmission of
	SARS-CoV-2 Involving a School-aged Child. Wisconsin Med Journal. 2021. In press. Temte JL,
	et al (including <b>Allen Bateman</b> ).
	Risk Factors for SARS-CoV-2 Infection and
	Presence of Anti-SARS-CoV-2 Antibodies among
	University Student Dormitory Residents,
	September-November, 2020. Open Forum
	Infectious Diseases. 2021. In Press. Segaloff H, et
	al (including Allen Bateman).
	Carbapenemase production among less-
	common Enterobacterales genera: 10 US sites,
	2018
	JAC-Antimicrobial Resistance, Volume 3, Issue 3,
	September 2021, dlab127: https://doi.org/10.1002/iacamr/dlab12
	dlab137; <u>https://doi.org/10.1093/jacamr/dlab13</u> <u>7</u>
	<u> </u>

		Alicia Shugart, et al (including Ann Valley, Megan Lasure) <u>Genetics</u> Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease <i>Kidney360</i> February 2021, 2 (2) 312-324; DOI: <u>https://doi.org/10.34067/KID.0001182019</u> Gauri Bhutani, Brad C. Astor, Didier A. Mandelbrot, Lori Mankowski-Gettle, Timothy Ziemlewicz, Shane A. Wells, Leah Frater-Rubsam, Vanessa Horner, Courtney Boyer, Jennifer Laffin	
May 2021	<i>Central States</i> <i>Water</i> magazine: Innovative Wastewater Monitoring for COVID-19 Mitigation – Part 2	and Arjang Djamali WSLH Senior Scientist Martin Shafer published a follow-up article about Wisconsin's COVID-19 wastewater surveillance program in <i>Central</i> <i>States Water</i> , the official magazine of the Central States Water Environment Association. The article starts on page 41 at <u>http://cswea.org/wp-</u> <u>content/uploads/2021/07/CS_Spring2021-</u> <u>rich.pdf</u>	Complete
June 10-11, 2021	Society of Forensic Toxicologists Executive Board meeting, Phoenix, AZ	Forensic Toxicology Section Director Amy Miles attended the annual Exec Board meeting for SOFT. Amy is currently serving as SOFT president.	Complete
June 25, 2021	National Institute of Justice Peer Review	Forensic Toxicology Section Director Amy Miles performed grant proposal reviews for NIJ to determine emergent research in forensic toxicology.	Complete
June 30, 2021	Medical Examiner draft bill review	Forensic Toxicology Section Director Amy Miles was asked to provide input on a bill draft that will soon circulate through Congress. The bill will increase funding for laboratories that support Medical Examiner death investigations and strengthen the Forensic Pathology workforce.	Ongoing

June 30, 2021	APHL webinar - PFAS	WSLH Organic Chemistry Supervisor Erin Mani was an invited panelist on the Association of Public Health Laboratories (APHL) "State Strategies to Build PFAS Testing Programs" webinar. Erin presented the WSLH's experience developing and implementing PFAS testing.	Complete
June 30, 2021	New England Journal of Medicine article – SARS-CoV-2 "real- world" vaccine effectiveness study	<ul> <li>WSLH Communicable Disease Division scientists developed a quantitative RT-PCR test for SARS- CoV-2 as part of a CDC-led study looking at the effectiveness in real-world conditions of the mRNA vaccines developed by Pfizer-BioNTech and Moderna. The results of the study were published in the June 30th <i>New England Journal</i> <i>of Medicine</i>.</li> <li>The study, which ran from December 14, 2020 to April 10, 2021, involved 3,975 health care personnel, first responders, and other essential and frontline workers from Arizona, Florida, Minnesota, Oregon, Texas and Utah. Study participants submitted nasal swab specimens on a weekly basis that were tested at the Marshfield Clinic Research Institute (qualitative RT-PCR testing) and the WSLH (quantitative RT-PCR testing to measure viral load, which is the amount of virus in the body).</li> <li>Based on the WSLH's long-standing experience and relationship with CDC on influenza testing and surveillance, CDC asked CDD Director Dr. Al Bateman and WSLH Virology Team Lead Erik Reisdorf to develop a quantitative RT-PCR test method that could measure viral loads for this project. The WSLH testing was performed by Microbiologists Erika Hanson and Kyley Guenther.</li> </ul>	Complete
July 1, 2021	Vanessa Horner promoted to Associate Professor	Vanessa Horner, PhD, FACMG, director of UW Cytogenetics and Molecular Genetics at the WSLH, has been promoted to Associate Professor in the UW Department of Pathology and Laboratory Medicine.	Complete
July 9, 2021	DHS Provider Webinar	WSLH Communicable Disease Division Director Dr. Allen Bateman presented at the DHS Provider	Complete

		Webinar about respiratory virus surveillance in Wisconsin, and how SARS-CoV-2 surveillance fits into statewide surveillance for influenza and other respiratory viruses.	
July 16, 2021	Interview with Wisconsin Public Radio	Forensic Toxicology Section Director Amy Miles was interviewed on WPR and provided information on Delta-8 and its current popularity.	Complete
July 17, 2021	UW Undiagnosed Genetic Disease Clinic	The WSLH Cytogenetics and Molecular Genetics Services laboratory is partnering with the UW Center for Human Genomics and Precision Medicine at the UW School of Medicine and Public Health (SMPH) on its recently opened UW Undiagnosed Genetic Disease Clinic, which is housed at the Waisman Center on the UW- Madison campus.	Ongoing
		WSLH Cytogenetics and Molecular Genetics Services Assistant Director Kaitlin Lenhart said the WSLH will have a multi-faceted role in the new venture.	
		"The Biotech center will be performing short- read whole genome sequencing. The WSLH Cytogenetics lab will act as a so-called 'specimen traffic controller'" Lenhart explains. "We will perform the upfront nucleic acid extraction and banking, and coordinate the distribution of the specimen to the appropriate secondary laboratories. In addition, we plan to offer our data analysis expertise and confirm any significant findings in a clinical setting, which can then be passed on to the patient."	
July 29-30, 2021	National Alliance to Stop Impaired Driving (NASID), Washington, DC	Forensic Toxicology Section Director Amy Miles was asked to present and attend the first meeting of NASID as the National Resource Toxicologist.	Complete
August 14-16, 2021	Drug, Alcohol and Impaired Driving (ADID) annual conference, Orlando, FL	Forensic Toxicology Section Director Amy Miles was asked to provide two workshop presentations during the annual DAID conference. Forensic Scientist Kimberle Glowacki attended the conference virtually.	Complete

August 18, 2021	APHL Opioids Biosurveillance Task Force (OBTF)	Forensic Toxicology Section Director Amy Miles has been asked to co-chair the OBTF with Rhode Island PHL Director, Dr. Ewa King. The current	Ongoing
		focus of the OBTF is neonatal abstinence syndrome and exposure to drugs of abuse.	